About Us

Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange (Ticker: KURN) since 2016. With operations in the Netherlands and the USA, we employ a growing team of 75 people.

To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to reduce spinal fusion failure rates. Our credentials:

• A commercial & research footprint that spans 3 continents and covers 19 markets
• >25,000 patients treated with MagnetOs worldwide
• 10 well-controlled Level I-III clinical trials initiated, with 3 Level I studies having been completed and meeting primary endpoints
• >150 years’ combined research experience in the field of biologics for spine fusion
• Our team of scientists has over 700 publications combined from multiple disciplines and industries
• >25 biologics-related patents
• 4 teams of internationally renowned clinical and scientific expert advisors, including 18 Key Opinion Leader (KOL) spine surgeons